1. Vaccination against SARS-CoV-2 using extracellular blebs derived from spike protein-expressing dendritic cells
- Author
-
Chung, Jee Young, Thone, Melissa N, Davies, Jenny E, Gach, Johannes S, Davies, D Huw, Forthal, Donald N, and Kwon, Young Jik
- Subjects
Emerging Infectious Diseases ,Biodefense ,Biotechnology ,Vaccine Related ,Infectious Diseases ,Lung ,Prevention ,Immunization ,3.4 Vaccines ,Prevention of disease and conditions ,and promotion of well-being ,Infection ,Good Health and Well Being ,Humans ,Antibodies ,Neutralizing ,Antibodies ,Viral ,COVID-19 ,Dendritic Cells ,SARS-CoV-2 ,Spike Glycoprotein ,Coronavirus ,Vaccination ,Controlled antigen presentation ,Dendritic cell -derived vesicles ,Extracellular blebs ,Vaccines ,Dendritic cell-derived vesicles ,Immunology - Abstract
COVID-19 has caused significant morbidity and mortality worldwide but also accelerated the clinical use of emerging vaccine formulations. To address the current shortcomings in the prevention and treatment of SARS-CoV-2 infection, this study developed a novel vaccine platform that closely mimics dendritic cells (DCs) in antigen presentation and T-cell stimulation in a cell-free and tunable manner. Genetically engineered DCs that express the SARS-CoV-2 spike protein (S) were chemically converted into extracellular blebs (EBs). The resulting EBs elicited potentially protective humoral immunity in vivo, indicated by the production of antibodies that potently neutralized S-pseudotyped virus, presenting EBs as a promising and safe vaccine.
- Published
- 2023